Group 1 - EVE Energy signed a procurement framework agreement with its affiliate, Smoore International, for continuous procurement of battery cells starting from January 1, 2026 [1] - Zhaoyi Information plans to issue H-shares and list on the Hong Kong Stock Exchange [1] - Fuke Environmental announced a change in its stock abbreviation to "Fuke Technology" effective November 26 [1] Group 2 - Dajia Weikang's shareholder and director terminated a share reduction plan ahead of schedule, having reduced 1% of total shares [2] - Aohong Electronics received approval from the China Securities Regulatory Commission for the issuance of convertible bonds [2] - Yingfeng Environment's controlling shareholder plans to issue exchangeable bonds not exceeding 1 billion yuan [2] Group 3 - Longshen Rongfa's subsidiary obtained a renewed drug production license covering various pharmaceutical products [4] - Xinhua News' subsidiary invested 15 million yuan in a fund with a total commitment of 221 million yuan [5] - Guang'an Aizhong appointed two new deputy general managers [6] Group 4 - Fosun Pharma's subsidiary's drug for gastric cancer treatment was included in the breakthrough therapy program by the National Medical Products Administration [7] - Nanjiao Foods reported a significant decline in October net profit due to rising raw material costs [8] - Nanfeng Co. won two nuclear power project bids totaling 928.7 million yuan [10] Group 5 - Puluo Pharmaceutical received a drug registration certificate for its Cefdinir capsules [11] - Liming Co.'s subsidiary received environmental approval for a new pesticide raw material project [12] - Longhua New Materials' expansion project for polyether polyols has commenced trial production [13] Group 6 - Pumen Technology's products received IVDR CE certification from TÜV Rheinland [15] - China Chemical reported new contracts worth 312.67 billion yuan from January to October [18] - China Nuclear Construction achieved new contracts totaling 123.84 billion yuan as of October [19] Group 7 - Changshu Bank's executives plan to purchase at least 550,000 shares of the bank [20] - Shandong Steel's subsidiary is applying for bankruptcy liquidation to focus on core business [21] - Huakang Clean is expected to win a bid for a purification system project worth 176 million yuan [23] Group 8 - Huawu Co. plans to internally transfer subsidiary equity [24] - Tianen Kang's subsidiary received clinical trial acceptance for a new drug [26] - Tianyi Medical's subsidiary obtained a medical device registration certificate for a blood dialysis product [27] Group 9 - Xuelang Environment is facing a pre-restructuring application from creditors [27] - Chitianhua's subsidiary resumed production after passing safety inspections [28] - Huaping Co.'s director plans to reduce 0.03% of company shares [30] Group 10 - Xizhuang Co. plans to establish a wholly-owned subsidiary in Singapore [31] - Ruisheng Intelligent's subsidiary won a 60.23 million yuan ICT project bid [32] - Junyi Digital plans to invest 120 million yuan in Guanghong Precision [33] Group 11 - Fuguang Co.'s controlling shareholder plans to increase holdings between 80 million to 150 million yuan [34] - Ganyue Express reported a 13.68% increase in logistics revenue in October [39] - Jiangsu Sop terminated its 2025 private placement plan [41] Group 12 - Langke Intelligent's shareholders plan to reduce a total of 1.68% of company shares [42] - Yuantong Express reported an 8.97% increase in express product revenue in October [45] - Jinbei Automotive plans to invest 158 million yuan to acquire 52% of Zhongtuo Technology [46]

泰恩康（301263）(301263.SZ)公告，公司控股子公司江苏博创园生物医药科技有限公司(简称"博创园") 于近日收到国家药品监督管理局签发的受理通知书，同意受理博创园提交的CKBA乳膏联合窄谱中波紫 外线(简称"NB-UVB")在2-12岁(含2岁)儿童非节段型白癜风受试者中的安全耐受性、疗效和药代动力学 特征的多中心、随机、双盲、安慰剂对照II期临床研究申请。 ...

智通财经APP讯，泰恩康(301263.SZ)公告，公司控股子公司江苏博创园生物医药科技有限公司(简称"博 创园")于近日收到国家药品监督管理局签发的受理通知书，同意受理博创园提交的CKBA乳膏联合窄谱 中波紫外线(简称"NB-UVB")在2-12岁(含2岁)儿童非节段型白癜风受试者中的安全耐受性、疗效和药代 动力学特征的多中心、随机、双盲、安慰剂对照II期临床研究申请。 ...

泰恩康公告，控股子公司江苏博创园生物医药科技有限公司于近日收到国家药品监督管理局签发的受理 通知书，同意受理博创园提交的CKBA乳膏联合窄谱中波紫外线在2-12岁（含2岁）儿童非节段型白癜 风受试者中的安全耐受性、疗效和药代动力学特征的多中心、随机、双盲、安慰剂对照II期临床研究申 请。 ...

格隆汇11月20日丨泰恩康(301263.SZ)公布，控股子公司江苏博创园生物医药科技有限公司（简称"博创 园"）于近日收到国家药品监督管理局签发的受理通知书，同意受理博创园提交的CKBA乳膏联合窄谱 中波紫外线（简称"NB-UVB"）在2-12岁（含2岁）儿童非节段型白癜风受试者中的安全耐受性、疗效 和药代动力学特征的多中心、随机、双盲、安慰剂对照II期临床研究申请。 ...

证券代码：301263 证券简称：泰恩康 公告编号：2025-076 广东泰恩康医药股份有限公司 关于控股子公司 CKBA 乳膏申报儿童白癜风 临床试验取得受理通知书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 广东泰恩康医药股份有限公司（以下简称"公司"）控股子公司江苏博创 园生物医药科技有限公司（以下简称"博创园"）于近日收到国家药品监督管 理局（以下简称"国家药监局"）签发的受理通知书，同意受理博创园提交的 CKBA 乳膏联合窄谱中波紫外线（以下简称"NB-UVB"）在 2-12 岁（含 2 岁） 儿童非节段型白癜风受试者中的安全耐受性、疗效和药代动力学特征的多中心、 随机、双盲、安慰剂对照 II 期临床研究申请。现将相关情况公告如下： 结论：根据《中华人民共和国行政许可法》第三十二条的规定，经审查， 决定予以受理。 二、后续流程 CKBA（抑制CD8+ T细胞向Tc1及Tc17分化，下调IFN-γ和IL-17的表达）与 NB-UVB的联合治疗，核心优势在于：CKBA改善皮肤区域免疫环境，阻止"白 斑"扩增；NB-UVB直接激活黑素干细胞，使其分 ...

Core Points - The company, Haitai Xinguang, announced the approval of the first grant of restricted stock under the 2025 restricted stock incentive plan during the ninth meeting of the fourth board of directors held on November 19, 2025 [2] - The grant date is set for November 19, 2025, with a grant price of 25 yuan per share [2] - A total of 800,000 shares of restricted stock will be granted to 15 incentive objects [2]

11月17日，泰恩康跌2.01%，成交额1.46亿元。两融数据显示，当日泰恩康获融资买入额2819.54万元， 融资偿还1648.56万元，融资净买入1170.98万元。截至11月17日，泰恩康融资融券余额合计9.93亿元。 融资方面，泰恩康当日融资买入2819.54万元。当前融资余额9.93亿元，占流通市值的7.59%，融资余额 超过近一年90%分位水平，处于高位。 融券方面，泰恩康11月17日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，广东泰恩康医药股份有限公司位于广东省汕头市龙湖区泰山北路万吉南二街8号A幢，成立 日期1999年1月22日，上市日期2022年3月29日，公司主营业务涉及代理运营及研发、生产、销售医药产 品、医疗器械、卫生材料并提供医药技术服务与技术转让等。主营业务收入构成为：肠胃用药 32.62%，眼科用药25.05%，中成药及外用药21.08%，两性健康用药21.06%，其他(补充)0.19%。 截至9月30日，泰恩康股东户数1.20万，较上期增加9.32%；人均 ...

Core Viewpoint - The company, TianKang, has officially announced the initiation of preclinical research for its innovative drug CKBA targeting Alzheimer's disease (AD), based on significant findings from a research team at Shanghai Jiao Tong University [1][2]. Group 1: Drug Development and Mechanism - CKBA is a first-in-class innovative drug that targets the newly identified MFE-2 pathway, which plays a crucial role in the lipid metabolism and neuroinflammation associated with AD [2][4]. - The drug demonstrates a differentiated advantage by being orally administered and capable of crossing the blood-brain barrier, showing improvements in cognitive function, reduction of neuroinflammation, and decreased Aβ plaque accumulation in AD model mice [4]. Group 2: Market Potential and Financial Outlook - The Alzheimer's drug market in China is projected to grow from approximately 6 billion yuan in 2023 to over 26 billion yuan by 2030, with a compound annual growth rate (CAGR) of 19.2%, while the global market is expected to reach 31.44 billion USD [4]. - The company anticipates submitting its phase I clinical application for CKBA in the second half of 2026, supported by cash flow from its existing generic drug business [4]. Group 3: Broader Product Pipeline and Growth Strategy - In addition to AD, CKBA is part of a broader pipeline that includes treatments for vitiligo and rosacea, with ongoing clinical trials showing promising results [5]. - The company is also expanding its generic and modified drug segments, with several products in the pipeline expected to contribute to revenue growth [5][6]. Group 4: Institutional Support and Market Confidence - The company has gained recognition from institutional investors, with significant increases in holdings from the basic pension insurance fund, indicating confidence in the company's growth potential [7][9]. - Management has shown commitment to the company's long-term success, with no plans for share reduction post-lockup and active participation in shareholding [9].

Core Viewpoint - The company announced the initiation of preclinical research for CKBA, a novel drug for Alzheimer's disease, highlighting its potential in addressing the growing patient population due to aging demographics [1][3]. Group 1: Alzheimer's Disease Research - Alzheimer's disease (AD) is facing two major challenges: unclear core pathogenic mechanisms and limited breakthroughs in traditional drug targets, necessitating new theoretical frameworks and drug solutions [1]. - The research published in "Nature Aging" reveals the critical role of the "lipid metabolism—microglial activation—neuroinflammation" axis in AD, establishing CKBA's new target MFE-2 as a valuable intervention point for innovative drug development [2]. - CKBA, derived from the active component AKBA of traditional Chinese medicine, has demonstrated a threefold effect in AD model mice: improving cognitive function, reducing neuroinflammation, and decreasing Aβ plaques, overcoming traditional drug limitations [4]. Group 2: Clinical Development Plans - The company plans to advance CKBA into clinical research for Alzheimer's disease, with a goal to initiate Phase I clinical trials in the second half of 2026 if progress is smooth [4]. - CKBA is also being explored for its potential in treating immune-related diseases beyond AD, marking the company's first step into the innovative drug sector [5]. Group 3: Other Indications and Market Potential - The company is conducting Phase III clinical trials for CKBA in treating vitiligo, a chronic autoimmune skin disease, with a significant market potential exceeding 100 billion yuan in China [5]. - CKBA's development for rosacea has also progressed, with plans to start patient medication by the end of the year and aim for new drug application approval by 2027 [6].